Accumulating evidence shows that NRF2 is overactivated in cancer cells, and that aberrant NRF2 signaling creates an environment that promotes tumorigenesis, invasiveness, and chemoresistance [9,10,11,12,13,14]. The gene discussed is NFE2L2; the disease is cancer.